Real-world outcomes of patients treated with ≥17 cycles of pembrolizumab monotherapy as first-line therapy and for previously treated advanced NSCLC: multicenter observational study in France

Respiratory Medicine and Research · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles